BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Antitope, Announces Antibody Research Agreement With NKT Therapeutics Inc.


4/9/2009 12:39:43 PM

Cambridge UK, 8th April 2009 - Antitope Ltd. ("Antitope") today announced a research agreement with NKT Therapeutics Inc ("NKT") for the generation of therapeutic monoclonal antibodies. Under the Agreement, Antitope will apply its proprietary Composite Human AntibodyTM technology for the generation of humanized antibodies for treatment of asthma and other chronic diseases.

"We are delighted to be working with NKT who we recognize as leaders in the biology and therapeutic applications of modulating Natural Killer T cells," said Dr Matthew Baker, Chief Scientific Officer and co-founder of Antitope Limited. "This partnership utilizes Antitope's expertise in engineering humanized antibodies devoid of T cell epitopes and complement NKT's innovations in developing novel therapeutics based on monoclonal antibodies targeting Natural Killer T cells."

"We greatly appreciate working with Antitope, with their deep pool of talent and experience in antibody engineering" said Dr Alem Truneh, Chief Scientific Officer and co-founder of NKT Therapeutics.

About Antitope

Antitope Ltd. is a privately-held Cambridge UK-based biotechnology company specializing in immunogenicity testing and the engineering of therapeutic antibodies/proteins with reduced immunogenicity. Antitope's proprietary Composite Human Antibody technology provides a novel solution to the detection and removal of T cell epitopes in antibodies/proteins through proprietary humanization and DeImmunisation technologies. Antitope has established multiple commercial relationships with leading biotechnology and pharmaceutical companies. For further information on Antitope visit http://www.antitope.co.uk/ or contact:

Dr Neil Butt

Business Development Director, Antitope Ltd.

Tel: +44 (0)1223 496190

Email: info@antitope.co.uk

About NKT Therapeutics Inc.

NKT Therapeutics, Inc. is a privately held biotechnology company focused on developing therapeutics based on unique immune cells called natural killer T (NKT) cells. The company's mission is to use its expertise to develop a pipeline of first-in-class NKT-based therapeutics to treat cancer, infectious diseases, autoimmune diseases, asthma and dermatitis. For more information on the company, please visit http://www.nktrx.com/.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES